Leading the clinical/regulatory program at Atox Bio, bringing it from pre IND meeting to completion of a multi center phase 2 study in the US and initiation of multi center Phase 3 study in the US. Led 3 successful clinical trials in the USResponsible for multiple successful iterations with FDA and EMA. Leading the pre-clinical research at Atox Bio, performed as global collaborations at leading research centers across US and EUResponsible for the academic activities of Atox Bio: publication, presentationsWriting and managing the grants application/contracts, obtaining substantial funding to Atox BioOverseeing the CMC development, Responsible to manage the IP status

Pre clinical development:Overall responsibility for bringing the lead compound into first human trials (Phase I)Regulatory affairs:Established and managed the regulatory affairs at Aposense. Developed and executed regulatory affairs strategy.Clinical development:Responsible for development of the clinical program at Aposense, up to multi-center phase II trialsResponsible for strategy, budget, clinical operations, peopleGlobal collaborations and activities: Led collaborative projects with major Pharma companies, Presented the company technology in multiple meeting with Pharma, US agencies (NCI), Investors, and Due-diligenceEstablished and managed a set of global investigator initiated studies (in US and EU)Management:Member of Aposense ManagementMember of the Board of directors of AposenseAcademic:Authored and co-authored scientific publicationsInvited lecturer to scientific conferences in the field of Nuclear Medicine, Oncology, Drug Development and Molecular ImagingServe as a reviewer of manuscripts submitted to the International Journal of Cancer and of abstracts submitted to the Society of Molecular Imaging for the World Molecular Imaging Congress (WMIC)

Drug DiscoveryOverall responsibility for product development from concept and molecule design to lead compound selection and characterization